Trial Profile
An in-vitro study of patients on deferasirox (DFX) treatment with Transfusion Dependent Thalassaemia (TDT) assessing Cardiac Iron Loading.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Feb 2016
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Thalassaemia
- Focus Biomarker; Pharmacodynamics
- 08 Feb 2016 New trial record